Skip to content
Sparfloxacin
Zagam (sparfloxacin) is a small molecule pharmaceutical. Sparfloxacin was first approved as Zagam on 1996-12-19. It is used to treat chlamydia infections, escherichia coli infections, haemophilus infections, klebsiella infections, and pneumonia amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sparfloxacin
Tradename
Company
Number
Date
Products
ZAGAMMylanN-020677 DISCN1996-12-19
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chlamydia infectionsEFO_0007205D002690A74.9
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
klebsiella infectionsEFO_1001353D007710—
pneumoniaEFO_0003106D011014J18
proteus infectionsEFO_1001130D011512—
salmonella infectionsEFO_1001418D012480A02.9
staphylococcal infections—D013203A49.01
streptococcal infectionsEFO_1001476D013290—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA09: Sparfloxacin
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic progressive multiple sclerosisD020528———123
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35——2—46
Relapsing-remitting multiple sclerosisD020529EFO_0003929——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSPARFLOXACIN
INNsparfloxacin
Description
Sparfloxacin is a quinolone, a quinolinemonocarboxylic acid, a N-arylpiperazine, a quinolone antibiotic and a fluoroquinolone antibiotic.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
Identifiers
PDB—
CAS-ID110871-86-8
RxCUI18469
ChEMBL IDCHEMBL850
ChEBI ID9212
PubChem CID60464
DrugBankDB01208
UNII IDQ90AGA787L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,558 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,564 adverse events reported
View more details